Corporate Banner
Satellite Banner
Crystallography
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Technologies Reports Third-Quarter 2012 Results

Published: Thursday, August 16, 2012
Last Updated: Monday, August 20, 2012
Bookmark and Share
Revenues were $1.72 billion for the third fiscal quarter ended July 31, 2012, 2 percent above one year ago.

Third-quarter GAAP net income was $243 million, or $0.69 per share. Last year's third-quarter GAAP net income was $330 million, or $0.92 per share.

During the third quarter, Agilent had intangible amortization of $32 million, acquisition and integration costs of $41 million, and asset impairment and write-down charges of $15 million. The company also recognized a tax benefit of $58 million. Excluding these items and $5 million of other net charges, Agilent reported third-quarter adjusted net income of $278 million, or $0.79 per share.

Bill Sullivan, Agilent president and CEO, said, "Agilent's performance in the fiscal third quarter did not meet our revenue and EPS guidance. We have clearly entered an environment of much slower growth, resulting in deals taking longer to close and customers delaying their order deliveries.

"Despite the global environment, however, we delivered a strong operating margin performance that underscores Agilent's ability to proactively respond to rapidly changing market conditions."
Electronic Measurement third-quarter revenues were down 1 percent over the prior year. Orders declined 4 percent from the same period last year. Growth in communications was driven by wireless manufacturing and was offset by weaker aerospace and defense and industrial demand.

Chemical Analysis revenues were flat with a year ago. Orders were down 7 percent. Food and forensics markets held steady, while petrochemical and energy were impacted by the global economy.

Life Sciences revenues grew 2 percent over last year, while orders declined 2 percent year over year. Growth in the pharma market was offset by a decline in academic and government.
Diagnostics and Genomics, which includes the recent Dako acquisition, had revenues of $106 million.

Agilent generated $240 million of cash from operations in the quarter. Third-quarter ROIC was 18 percent.

Fiscal fourth-quarter 2012 revenues are expected to be in the range of $1.76 billion to $1.78 billion. Fiscal fourth-quarter non-GAAP earnings are expected to be in the range of $0.80 to $0.82 per share.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Supports International Year of Crystallography
2014 partnership with international union of crystallography aimed at educating, inspiring young scientists.
Monday, January 27, 2014
Agilent Reports Fourth-Quarter Results
Agilent Technologies reported orders up 4 percent over one year ago to $1.83 billion with revenues of $1.72 billion, down 3 percent compared with one year ago.
Monday, November 18, 2013
Agilent Recognized as 2013 Laboratory Analytical Instrumentation Company of the Year in China
The company ranked highest in industry for leadership, growth, innovation and customer service by Frost & Sullivan.
Tuesday, August 20, 2013
Agilent Technologies Appoints Ron Nersesian President and COO
The company's board of directors has appointed Ron Nersesian Agilent president and chief operating officer, effective immediately.
Thursday, November 15, 2012
Agilent Technologies Prices $400 Million of Senior Notes
Agilent intends to use the net proceeds from the offering for general corporate purposes, which will include the repayment of its 4.45 percent senior notes due in September 2012.
Tuesday, September 11, 2012
Agilent Technologies Ships 300th X-Ray Crystallography System
Recipient is University of Oxford’s Chemical Crystallography Laboratory.
Monday, September 06, 2010
Scientific News
'Molecular Movie' Opens Door to New Cancer Treatments
An international team of scientists led by the University of Liverpool has produced a 'structural movie' revealing the step-by-step creation of an important naturally occurring chemical in the body that plays a role in some cancers.
Crouching Protein, Hidden Enzyme
A new study led by scientists at The Scripps Research Institute (TSRI) and the University of California (UC), Berkeley shows how a crucial molecular enzyme starts in a tucked-in somersault position and flips out when it encounters the right target.
Spotlight on Acoustic Liquid Handling
Journal of Laboratory Automation special issue highlights how acoustic liquid handling enables breakthrough innovations.
3D Images of Enzymes May Lead to Improved Antibiotics
Research advances understanding of how crucial proteins function.
Supply Chain
Chemists discover how a single enzyme maintains a cell’s pool of DNA building blocks.
Seeing DROSHA for the First Time
IBS team gets the first glimpse of elusive protein structure.
Scientists Blueprint Tiny Cellular ‘Nanomachine’
Scientists have drawn up molecular blueprints of a tiny cellular ‘nanomachine’, whose evolution is an extraordinary feat of nature, by using one of the brightest X-ray sources on Earth.
Pioneering Brain Cancer Technique Could Lead to Better Prognosis for Patients
4,000th paper published from Diamond research could improve outcomes for brain cancer sufferers.
Big Moves in Protein Structure Prediction and Design
Custom design with atomic level accuracy enables researchers to craft a whole new world of proteins.
Pushing Drug Discovery Forward
A new study, led by scientists at The Scripps Research Institute (TSRI), shows how different pharmaceutical drugs hit either the “on” or “off” switch of a signaling protein linked to asthma, obesity and type 2 diabetes.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!